Scaling haplospecific antisense oligonucleotides from N-of-1 to broad use in genetic disease populations by diplotyping.
American journal of human genetics · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansOligonucleotides, AntisenseHaplotypesPolymorphism, Single NucleotideNAV1.2 Voltage-Gated Sodium ChannelNeurodevelopmental DisordersWhole Genome SequencingAllelesGenetic Diseases, InbornMaleN-of-1 therapyTruPathantisense oligonucleotideautismbasket trialcausal variantdisease modifying therapyepilepsygenetic diseasegenetic therapygenome sequencinghaplospecificityhaplotypeindividualized therapyinvestigational new drugplausible mechanism frameworkscalabilitysingle-nucleotide polymorphism
Come citare questo studio
Olivia Kim-McManus, Pagé Goddard, Shahad Olsson, Liana Protopsaltis, Joseph Gleeson, Qing Zhang, Nafeesa Kahn, Ali Crawford, Stephen F Kingsmore. (2026). Scaling haplospecific antisense oligonucleotides from N-of-1 to broad use in genetic disease populations by diplotyping.. American journal of human genetics. DOI: 10.1016/j.ajhg.2026.08.017
Consulta la pubblicazione originale ↗